GFR-话题@MedSci

#GFR#

483篇内容 | 6242人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1534540, encodeId=1117153454050, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Eur Radiol:造影剂所导致的GFR轻度降低是否会诱发肾损伤？, objectType=article, longId=208334, objectId=c6f520833447, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6f520833447, replyNumber=0, likeNumber=0, createdTime=2021-03-15, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6f520833447, moduleTitle=Eur Radiol:造影剂所导致的GFR轻度降低是否会诱发肾损伤？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6f520833447)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534539, encodeId=faa415345390a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=艾力斯三代EGFR-TKI甲磺酸伏美替尼获NMPA批准上市, objectType=article, longId=208133, objectId=ea64208133ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea64208133ab, replyNumber=0, likeNumber=79, createdTime=2021-03-09, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea64208133ab, moduleTitle=艾力斯三代EGFR-TKI甲磺酸伏美替尼获NMPA批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea64208133ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534538, encodeId=0cca1534538ce, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=第二个国产三代EGFR-TKI获批上市, objectType=article, longId=208092, objectId=47f52080927e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=47f52080927e, replyNumber=0, likeNumber=113, createdTime=2021-03-09, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=47f52080927e, moduleTitle=第二个国产三代EGFR-TKI获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=47f52080927e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534537, encodeId=b6ee153453e3d, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cancer Discov：新型EGFR抑制剂Mobocertinib用于携带EGFRex20ins突变的NSCLC患者的疗效和安全性, objectType=article, longId=207727, objectId=85a920e727bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85a920e727bb, replyNumber=0, likeNumber=139, createdTime=2021-03-01, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85a920e727bb, moduleTitle=Cancer Discov：新型EGFR抑制剂Mobocertinib用于携带EGFRex20ins突变的NSCLC患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85a920e727bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534536, encodeId=a42a153453647, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=武田呈报Mobocertinib治疗先前接受过含铂化疗的EGFR外显子20插入+ mNSCLC患者的阳性结果, objectType=article, longId=206667, objectId=b05220666ed0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b05220666ed0, replyNumber=0, likeNumber=91, createdTime=2021-02-04, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b05220666ed0, moduleTitle=武田呈报Mobocertinib治疗先前接受过含铂化疗的EGFR外显子20插入+ mNSCLC患者的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b05220666ed0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534535, encodeId=0e82153453563, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Pemigatinib治疗FGFR2融合或重排的晚期胆管癌，CHMP持积极评价, objectType=article, longId=206525, objectId=468b20652504, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=468b20652504, replyNumber=0, likeNumber=50, createdTime=2021-02-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=468b20652504, moduleTitle=Pemigatinib治疗FGFR2融合或重排的晚期胆管癌，CHMP持积极评价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=468b20652504)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534534, encodeId=622e153453488, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=WCLC 2020：Patritumab Deruxtecan治疗EGFR突变的NSCLC患者, objectType=article, longId=206511, objectId=cbe82065113c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbe82065113c, replyNumber=0, likeNumber=97, createdTime=2021-02-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbe82065113c, moduleTitle=WCLC 2020：Patritumab Deruxtecan治疗EGFR突变的NSCLC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbe82065113c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534533, encodeId=b5d1153453388, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=WCLC 2020：Tagrisso可显著延长EGFR突变非小细胞肺患者的无病生存期, objectType=article, longId=206510, objectId=103720651045, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=103720651045, replyNumber=0, likeNumber=85, createdTime=2021-02-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=103720651045, moduleTitle=WCLC 2020：Tagrisso可显著延长EGFR突变非小细胞肺患者的无病生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=103720651045)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534532, encodeId=1ca01534532b1, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=WCLC 2020：Neratinib治疗EGFR外显子18突变的转移性非小细胞肺癌，II期研究取得相对积极的结果, objectType=article, longId=206509, objectId=3eca206509d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3eca206509d2, replyNumber=0, likeNumber=92, createdTime=2021-02-02, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3eca206509d2, moduleTitle=WCLC 2020：Neratinib治疗EGFR外显子18突变的转移性非小细胞肺癌，II期研究取得相对积极的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3eca206509d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534531, encodeId=5511153453178, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Acta Neuropathologica: 在一系列83例H3F3A K27M突变的弥漫性中线胶质瘤中，FGFR1突变与较好的预后相关 , objectType=article, longId=206259, objectId=280e2062593b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=280e2062593b, replyNumber=0, likeNumber=0, createdTime=2021-01-27, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=280e2062593b, moduleTitle=Acta Neuropathologica: 在一系列83例H3F3A K27M突变的弥漫性中线胶质瘤中，FGFR1突变与较好的预后相关 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=280e2062593b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534530, encodeId=1e331534530f7, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Clin Cancer Res：奥希替尼联合雷莫芦单抗治疗EGFR突变型NSCLC具有显著疗效, objectType=article, longId=206216, objectId=c8ee2062161f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8ee2062161f, replyNumber=0, likeNumber=120, createdTime=2021-01-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8ee2062161f, moduleTitle=Clin Cancer Res：奥希替尼联合雷莫芦单抗治疗EGFR突变型NSCLC具有显著疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8ee2062161f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534529, encodeId=ba8e1534529a4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Clin Cancer Res：抑制FGFR可克服皮肤鳞状细胞癌对EGFR靶向治疗的耐药性, objectType=article, longId=206215, objectId=5d49206215f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d49206215f3, replyNumber=0, likeNumber=118, createdTime=2021-01-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d49206215f3, moduleTitle=Clin Cancer Res：抑制FGFR可克服皮肤鳞状细胞癌对EGFR靶向治疗的耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d49206215f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534528, encodeId=79d51534528a6, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Clin Oncol：吉非替尼辅助治疗EGFR突变型NSCLC的5年预后, objectType=article, longId=204877, objectId=93f62048e720, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93f62048e720, replyNumber=0, likeNumber=111, createdTime=2020-12-27, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93f62048e720, moduleTitle=J Clin Oncol：吉非替尼辅助治疗EGFR突变型NSCLC的5年预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93f62048e720)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534527, encodeId=ac74153452e2b, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=J Thromb Haemost：ALK和EGFR突变型肺癌患者血栓栓塞风险分析, objectType=article, longId=204723, objectId=251b204e2375, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=251b204e2375, replyNumber=0, likeNumber=102, createdTime=2020-12-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=251b204e2375, moduleTitle=J Thromb Haemost：ALK和EGFR突变型肺癌患者血栓栓塞风险分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=251b204e2375)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534526, encodeId=240f153452684, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=JCO：BLOOM研究——Osimertinib在EGFRm和LM非小细胞肺癌患者中的应用, objectType=article, longId=204599, objectId=0719204599a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0719204599a7, replyNumber=0, likeNumber=119, createdTime=2020-12-18, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0719204599a7, moduleTitle=JCO：BLOOM研究——Osimertinib在EGFRm和LM非小细胞肺癌患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0719204599a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534525, encodeId=07e21534525bb, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Cell Death Differ：HPV介导EGFR信号转导通路促进宫颈癌细胞的增殖, objectType=article, longId=204443, objectId=05932044432b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=05932044432b, replyNumber=0, likeNumber=118, createdTime=2020-12-14, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=05932044432b, moduleTitle=Cell Death Differ：HPV介导EGFR信号转导通路促进宫颈癌细胞的增殖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=05932044432b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534524, encodeId=c7611534524f4, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=CELL：组蛋白和PDGFRA双重突变促进胶质瘤发生, objectType=article, longId=204136, objectId=706a204136dc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=706a204136dc, replyNumber=0, likeNumber=111, createdTime=2020-12-06, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=706a204136dc, moduleTitle=CELL：组蛋白和PDGFRA双重突变促进胶质瘤发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=706a204136dc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534523, encodeId=02cd15345239a, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=阿斯利康的EGFR抑制剂osimertinib辅助治疗非小细胞肺癌，获得FDA优先审查, objectType=article, longId=202339, objectId=864620233978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=864620233978, replyNumber=0, likeNumber=84, createdTime=2020-10-22, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=864620233978, moduleTitle=阿斯利康的EGFR抑制剂osimertinib辅助治疗非小细胞肺癌，获得FDA优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=864620233978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534522, encodeId=9f861534522ea, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=Oncogene：EGFR上调的LIFR能够促进前列腺癌SUCLG2依赖的去势抗性和神经内分泌分化, objectType=article, longId=201986, objectId=dbef2019865c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dbef2019865c, replyNumber=0, likeNumber=83, createdTime=2020-10-13, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dbef2019865c, moduleTitle=Oncogene：EGFR上调的LIFR能够促进前列腺癌SUCLG2依赖的去势抗性和神经内分泌分化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dbef2019865c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1534521, encodeId=ec0f153452112, content=<a href='/topic/show?id=22b3e9887e' target=_blank style='color:#2F92EE;'>#GFR#</a>, objectTitle=泰瑞沙在早期EGFR突变肺癌辅助治疗中可降低82%脑部复发风险, objectType=article, longId=201192, objectId=608e2011928b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=608e2011928b, replyNumber=0, likeNumber=78, createdTime=2020-09-26, rootId=0, userName=liuyiping, userId=f0a812532020, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=608e2011928b, moduleTitle=泰瑞沙在早期EGFR突变肺癌辅助治疗中可降低82%脑部复发风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=608e2011928b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GFR

2020-05-29

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Eur Radiol:造影剂所导致的GFR轻度降低是否会诱发肾损伤？

2021-03-15

liuyiping (审核中...)

前往app查看评论内容

#GFR#

艾力斯三代EGFR-TKI甲磺酸伏美替尼获NMPA批准上市

2021-03-09

liuyiping (审核中...)

前往app查看评论内容

#GFR#

第二个国产三代EGFR-TKI获批上市

2021-03-09

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cancer Discov：新型EGFR抑制剂Mobocertinib用于携带EGFRex20ins突变的NSCLC患者的疗效和安全性

2021-03-01

liuyiping (审核中...)

前往app查看评论内容

#GFR#

武田呈报Mobocertinib治疗先前接受过含铂化疗的EGFR外显子20插入+ mNSCLC患者的阳性结果

2021-02-04

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Pemigatinib治疗FGFR2融合或重排的晚期胆管癌，CHMP持积极评价

2021-02-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

WCLC 2020：Patritumab Deruxtecan治疗EGFR突变的NSCLC患者

2021-02-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

WCLC 2020：Tagrisso可显著延长EGFR突变非小细胞肺患者的无病生存期

2021-02-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

WCLC 2020：Neratinib治疗EGFR外显子18突变的转移性非小细胞肺癌，II期研究取得相对积极的结果

2021-02-02

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Acta Neuropathologica: 在一系列83例H3F3A K27M突变的弥漫性中线胶质瘤中，FGFR1突变与较好的预后相关

2021-01-27

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Clin Cancer Res：奥希替尼联合雷莫芦单抗治疗EGFR突变型NSCLC具有显著疗效

2021-01-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Clin Cancer Res：抑制FGFR可克服皮肤鳞状细胞癌对EGFR靶向治疗的耐药性

2021-01-26

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Clin Oncol：吉非替尼辅助治疗EGFR突变型NSCLC的5年预后

2020-12-27

liuyiping (审核中...)

前往app查看评论内容

#GFR#

J Thromb Haemost：ALK和EGFR突变型肺癌患者血栓栓塞风险分析

2020-12-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

JCO：BLOOM研究——Osimertinib在EGFRm和LM非小细胞肺癌患者中的应用

2020-12-18

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Cell Death Differ：HPV介导EGFR信号转导通路促进宫颈癌细胞的增殖

2020-12-14

liuyiping (审核中...)

前往app查看评论内容

#GFR#

CELL：组蛋白和PDGFRA双重突变促进胶质瘤发生

2020-12-06

liuyiping (审核中...)

前往app查看评论内容

#GFR#

阿斯利康的EGFR抑制剂osimertinib辅助治疗非小细胞肺癌，获得FDA优先审查

2020-10-22

liuyiping (审核中...)

前往app查看评论内容

#GFR#

Oncogene：EGFR上调的LIFR能够促进前列腺癌SUCLG2依赖的去势抗性和神经内分泌分化

2020-10-13

liuyiping (审核中...)

前往app查看评论内容

#GFR#

泰瑞沙在早期EGFR突变肺癌辅助治疗中可降低82%脑部复发风险

2020-09-26

科室
- - 订阅+
  - 更多科室
工具
服务